This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.

Last Week Tonight joined a long and growing list of media outlets that have added fuel to the hype of psychedelic medicalization. By omitting the potential risks and actual harms associated with psychedelic-assisted therapy, this messaging increases the risk to the public by presenting unrealistic expectations about experimental treatments.

As I became activated to defend something bigger than my own immediate welfare, a shift took place—a shift toward seeing reality as a singular entity as opposed to a bunch of disjointed parts.

So much of the conversation surrounding sex, like that surrounding drugs, is fear-based and chock full of negativity.

We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacism, capitalism, and imperialism.

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

The Church of Psilomethoxin claims it’s the victim of “psychedelic capitalism,” but almost everything it claims is wrong.

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.